About Tilt Biotherapeutics

Sponsor retains sole responsibility for content.

TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials,...

TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.

Contact Tilt Biotherapeutics

More About Tilt Biotherapeutics

Therapeutic Areas
  • Oncology
Technologies
  • Biologics
  • Nucleic acids
  • Vaccines
Company Type
  • Biotechnology – Therapeutics
State of Ownership
  • Private
Sponsorship Group
  • Networker